DDW is delighted to announce an exclusive event, supported by SPT Labtech, that will allow you to gain knowledge on kinetic assay design and take this forward to produce assays that deliver hits with higher physiological relevance.
Pharmacology expert Dr Nick Holliday, chief scientific officer, Excellerate Bioscience, will lead this session that will focus on the importance of kinetic assays in drug discovery. There are limited spaces left for this event. If you are an assay developer, screening scientist or drug discovery research scientist, register here.
What you will gain from this event:
- How association and dissociation rate constants describe compound binding kinetics
- The potential clinical benefits of optimising kinetic constants when compound profiling
- The wider relevance of signalling kinetics in determining therapeutic effects
- How experts in molecular and pharmacology are utilising lab automation instruments
- The advantages you can gain from collaborating with an expert CRO
Sharing his 25 years’ experience in the molecular pharmacology of receptors and other drug targets, Dr Holliday will use case studies from the CNS and respiratory disease areas and highlight the benefits of optimising binding on and off rates for duration of action and generation of kinetic selectivity, together with improved inhibitor and antagonist effects.
He will also consider the need to map the kinetics of signalling to better predict the desired functional therapeutic outcome in cells or tissues.
Putting the dynamics into compound profiling: using kinetic assays to shape drug discovery, will take place on 10 December at 3PM (BST). It is hosted by DDW and supported by SPT Labtech. It will be delivered by Excellerate Bioscience, an innovative contract research organisation known for its excellence in molecular and cellular pharmacology.
Date: 10 December 2020
Time: 3pm UK BST
Cost: Free-to-attend (participation subject to approval)
Click here to register for free